首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Double Mutation in the pfmdr1 Gene Is Associated with Emergence of Chloroquine-Resistant Plasmodium falciparum Malaria in Eastern India
【2h】

Double Mutation in the pfmdr1 Gene Is Associated with Emergence of Chloroquine-Resistant Plasmodium falciparum Malaria in Eastern India

机译:pfmdr1基因的双重突变与印度东部抗氯喹的恶性疟原虫疟疾的出现有关。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malaria is a major public health problem in tropical and subtropical countries, including India. This study elucidates the cause of chloroquine treatment failure (for Plasmodium falciparum infection) before the introduction of artemisinin combination therapy. One hundred twenty-six patients were randomized to chloroquine treatment, and the therapeutic efficacy was monitored from days 1 to 28. An in vitro susceptibility test was performed with all isolates. Parasitic DNA was isolated, followed by PCR and restriction digestion of different codons of the pfcrt gene (codons 72 to 76) and the pfmdr1 gene (N86Y, Y184F, S1034C, N1042D, and D1246Y). Finally, sequencing was done to confirm the mutations. Forty-three (34.13%) early treatment failure cases and 16 (12.69%) late treatment failure cases were observed after chloroquine treatment. In vitro chloroquine resistance was found in 103 isolates (81.75%). Twenty-six (60.47%) early treatment failure cases and 6 (37.5%) late treatment failure cases were associated with the CVMNK->YYSN>Y allele (the underlined amino acids are those that were mutated). Moreover, the CV>IEK->YYSN>Y allele was found in 8 early treatment failure (18.60%) and 2 late treatment failure (12.5%) cases. The presence of the wild-type pfcrt (CVMNK) and pfmdr1 (>YYSN>Y) double mutant allele in chloroquine-nonresponsive cases was quite uncommon. In vivo chloroquine treatment failure and in vitro chloroquine resistance were strongly correlated with the CVMNK->YYSN>Y and CV>IEK->YYSN>Y haplotypes (P < 0.01).
机译:疟疾是包括印度在内的热带和亚热带国家的主要公共卫生问题。这项研究阐明了在引入青蒿素联合治疗之前氯喹治疗失败的原因(用于恶性疟原虫感染)。 126名患者被随机分配接受氯喹治疗,并在第1至28天监测疗效。对所有分离株进行体外药敏试验。分离寄生DNA,然后PCR和pfcrt基因(第72-76位密码子)和pfmdr1基因(N86Y,Y184F,S1034C,N1042D和D1246Y)的不同密码子的限制性酶切和限制性消化。最后,进行测序以确认突变。氯喹治疗后观察到43例(34.13%)早期治疗失败病例和16例(12.69%)晚期治疗失败病例。在103个分离株中发现了体外对氯喹的耐药性(81.75%)。与CVMNK- > Y YSN > Y 等位基因(带下划线的氨基酸)相关的有26例(60.47%)早期治疗失败病例和6例(37.5%)晚期治疗失败病例是那些被突变的)。此外,在8个早期治疗失败(18.60%)和2个晚期治疗失败(12.5)中发现了CV > IE K- > Y YSN > Y 等位基因%)个案例。在对氯喹无反应的病例中,野生型pfcrt(CVMNK)和pfmdr1(> Y YSN > Y )双突变等位基因的存在非常罕见。体内氯喹治疗失败和体外对氯喹的抵抗力与CVMNK- > Y YSN > Y 和CV > IE IEK Y YSN > Y 单倍型(P <0.01)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号